JP2010515081A5 - - Google Patents

Download PDF

Info

Publication number
JP2010515081A5
JP2010515081A5 JP2009544971A JP2009544971A JP2010515081A5 JP 2010515081 A5 JP2010515081 A5 JP 2010515081A5 JP 2009544971 A JP2009544971 A JP 2009544971A JP 2009544971 A JP2009544971 A JP 2009544971A JP 2010515081 A5 JP2010515081 A5 JP 2010515081A5
Authority
JP
Japan
Prior art keywords
administered
composition
receptor agonist
adenosine receptor
partial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009544971A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010515081A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/050117 external-priority patent/WO2008086096A2/en
Publication of JP2010515081A publication Critical patent/JP2010515081A/ja
Publication of JP2010515081A5 publication Critical patent/JP2010515081A5/ja
Pending legal-status Critical Current

Links

JP2009544971A 2007-01-03 2008-01-03 心筋灌流画像化 Pending JP2010515081A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87852907P 2007-01-03 2007-01-03
PCT/US2008/050117 WO2008086096A2 (en) 2007-01-03 2008-01-03 Myocardial perfusion imaging

Publications (2)

Publication Number Publication Date
JP2010515081A JP2010515081A (ja) 2010-05-06
JP2010515081A5 true JP2010515081A5 (enExample) 2011-02-24

Family

ID=39485181

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009544971A Pending JP2010515081A (ja) 2007-01-03 2008-01-03 心筋灌流画像化

Country Status (6)

Country Link
US (1) US20080267861A1 (enExample)
EP (1) EP2099360A2 (enExample)
JP (1) JP2010515081A (enExample)
CA (1) CA2673653A1 (enExample)
MX (1) MX2009007071A (enExample)
WO (1) WO2008086096A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
CA2671940A1 (en) 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
WO2004011010A1 (en) * 2002-07-29 2004-02-05 Cv Therapeutics, Inc. Myocardial perfusion imaging using a2a receptor agonists
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
EP1802317A2 (en) * 2004-10-20 2007-07-04 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists
CA2640089C (en) 2006-02-03 2013-07-23 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
CA2655310A1 (en) * 2006-06-22 2008-05-29 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
MX2009002299A (es) * 2006-09-01 2009-03-20 Cv Therapeutics Inc Metodos y composiciones para incrementar la tolerancia del paciente durante metodos de formacion de imagenes del miocardio.
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
WO2008042796A2 (en) * 2006-09-29 2008-04-10 Cv Therapeutics, Inc. Methods for myocardial imaging in patients having a history of pulmonary disease
EP2309919B1 (en) 2008-07-10 2019-03-06 Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO Functional optical coherent imaging
KR20110063556A (ko) * 2008-09-29 2011-06-10 길리애드 사이언시즈, 인코포레이티드 다검출 전산화 단층 촬영법에 사용하기 위한 ａ-２-알파 수용체 길항제와 속도 조절제의 조합물
WO2012061721A1 (en) * 2010-11-05 2012-05-10 Alleghney-Singer Research Institute Method and system for recommending a decision based on combined entity modeling
US9072490B2 (en) * 2010-12-20 2015-07-07 Toshiba Medical Systems Corporation Image processing apparatus and image processing method
US10575737B2 (en) * 2012-04-27 2020-03-03 Novadaq Technologies ULC Optical coherent imaging medical device
WO2017059302A1 (en) * 2015-09-30 2017-04-06 Cedars-Sinai Medical Center Robust myocardial blood oxygen level dependent magnetic resonance imaging with long-acting coronary vasodilators
EP3784118A4 (en) 2018-04-26 2022-01-05 Cedars-Sinai Medical Center MYOCARDIAL BLOOD OXYGEN LEVEL DEPENDENT MAGNETIC RESONANCE TOMOGRAPHY WITH HIGH TIME RESOLUTION

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4120947A (en) * 1976-03-31 1978-10-17 Cooper Laboratories, Inc. Xanthine compounds and method of treating bronchospastic and allergic diseases
US4089959A (en) * 1976-03-31 1978-05-16 Cooper Laboratories, Inc. Long-acting xanthine bronchodilators and antiallergy agents
SE7810946L (sv) * 1978-10-20 1980-04-21 Draco Ab Metod att behandla kronisk obstruktiv luftvegssjukdom
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4696932A (en) * 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives
JPS6299395A (ja) * 1985-10-25 1987-05-08 Yamasa Shoyu Co Ltd ２−アルキニルアデノシンおよび抗高血圧剤
US4968697A (en) * 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) * 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5070877A (en) * 1988-08-11 1991-12-10 Medco Research, Inc. Novel method of myocardial imaging
DE3831430A1 (de) * 1988-09-15 1990-03-22 Bayer Ag Substituierte 4-heterocyclyloximino-pyrazolin-5-one, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
US5270304A (en) * 1988-11-15 1993-12-14 Yamasa Shoyu Kabushiki Kaisha Therapeutic 2-alkynyl adenosine agent for ischemic diseases of the heart or brain
WO1990015812A1 (en) * 1989-06-20 1990-12-27 Yamasa Shoyu Kabushiki Kaisha Intermediate for 2-alkynyladenosine synthesis, production of said intermediate, production of 2-alkynyladenosine from said intermediate, and stable 2-alkynyladenosine derivative
US5032252A (en) * 1990-04-27 1991-07-16 Mobil Oil Corporation Process and apparatus for hot catalyst stripping in a bubbling bed catalyst regenerator
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5189027A (en) * 1990-11-30 1993-02-23 Yamasa Shoyu Kabushiki Kaisha 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases
JP2740362B2 (ja) * 1991-02-12 1998-04-15 ヤマサ醤油株式会社 安定な固体状２‐オクチニルアデノシンおよびその製造法
US5516894A (en) * 1992-03-11 1996-05-14 The General Hospital Corporation A2b -adenosine receptors
IT1254915B (it) * 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
US5705491A (en) * 1992-10-27 1998-01-06 Nippon Zoki Pharmaceutical Co., Ltd. Adenosine deaminase inhibitor
CA2112031A1 (en) * 1992-12-24 1994-06-25 Fumio Suzuki Xanthine derivatives
US5477857A (en) * 1993-09-10 1995-12-26 Discovery Therapeutics, Inc. Diagnostic uses of hydrazinoadenosines
WO1995023148A1 (en) * 1994-02-23 1995-08-31 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivative
US5704491A (en) * 1995-07-21 1998-01-06 Cummins-Allison Corp. Method and apparatus for discriminating and counting documents
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
US6514949B1 (en) * 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US6448235B1 (en) * 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US5854081A (en) * 1996-06-20 1998-12-29 The University Of Patent Foundation Stable expression of human A2B adenosine receptors, and assays employing the same
US5780481A (en) * 1996-08-08 1998-07-14 Merck & Co., Inc. Method for inhibiting activation of the human A3 adenosine receptor to treat asthma
US5776960A (en) * 1996-10-16 1998-07-07 Buckman Laboratories International, Inc. Synergistic antimicrobial compositions containing an ionene polymer and a pyrithione salt and methods of using the same
US5770716A (en) * 1997-04-10 1998-06-23 The Perkin-Elmer Corporation Substituted propargylethoxyamido nucleosides, oligonucleotides and methods for using same
US6026317A (en) * 1998-02-06 2000-02-15 Baylor College Of Medicine Myocardial perfusion imaging during coronary vasodilation with selective adenosine A2 receptor agonists
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6322771B1 (en) * 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6368573B1 (en) * 1999-11-15 2002-04-09 King Pharmaceuticals Research And Development, Inc. Diagnostic uses of 2-substituted adenosine carboxamides
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
US6552023B2 (en) * 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
US6677336B2 (en) * 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
CA2671940A1 (en) * 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
US6387913B1 (en) * 2000-12-07 2002-05-14 S. Jamal Mustafa Method of treating airway diseases with combined administration of A2B and A3 adenosine receptor antagonists
US6670334B2 (en) * 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
US6995148B2 (en) * 2001-04-05 2006-02-07 University Of Pittsburgh Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy
US6599283B1 (en) * 2001-05-04 2003-07-29 Cv Therapeutics, Inc. Method of preventing reperfusion injury
US6919804B1 (en) * 2001-05-08 2005-07-19 Vultron Incorporated Passenger detection system for vehicles
EP1389183B1 (en) * 2001-05-14 2010-03-03 Novartis AG Sulfonamide derivatives
US20030235555A1 (en) * 2002-04-05 2003-12-25 David Shealey Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
AU2002359365B2 (en) * 2001-11-09 2008-07-10 Gilead Sciences, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
WO2004011010A1 (en) * 2002-07-29 2004-02-05 Cv Therapeutics, Inc. Myocardial perfusion imaging using a2a receptor agonists
NZ548794A (en) * 2004-01-27 2009-07-31 Cv Therapeutics Inc Myocardial perfusion imaging using adenosine receptor agonists
EP2311462A1 (en) * 2004-10-15 2011-04-20 Cv Therapeutics, Inc. Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
EP1802317A2 (en) * 2004-10-20 2007-07-04 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists
BRPI0606662A2 (pt) * 2005-01-12 2010-02-09 King Pharmaceuticals Res & Dev métodos para diagnosticar a disfunção miocárdica, a doença da artéria coronária, a disfunção ventricular causada pela doença da artéria coronária, anormalidades de perfusão, para diagnosticar a presença e avaliar a severidade da doença da artéria coronária e a severidade da disfunção ventricular e a disfunção miocárdica, e, kit
CA2640089C (en) * 2006-02-03 2013-07-23 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
CA2655310A1 (en) * 2006-06-22 2008-05-29 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
MX2009002299A (es) * 2006-09-01 2009-03-20 Cv Therapeutics Inc Metodos y composiciones para incrementar la tolerancia del paciente durante metodos de formacion de imagenes del miocardio.
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
WO2008042796A2 (en) * 2006-09-29 2008-04-10 Cv Therapeutics, Inc. Methods for myocardial imaging in patients having a history of pulmonary disease

Similar Documents

Publication Publication Date Title
JP2010502649A5 (enExample)
JP2011502101A5 (enExample)
RU2009106862A (ru) Способы и композиции, повышающие переносимость пациентом методов визуализации миокарда
JP2005538190A5 (enExample)
NO20072540L (no) Anvendelse av A2A-adenosinreseptoragonist
US20150018299A1 (en) Treatment of liver conditions
CA2492855A1 (en) Myocardial perfusion imaging using a2a receptor agonists
WO2009143101A3 (en) Gastrin releasing peptide compounds
AU2020203316B2 (en) Novel regimes of FXR agonists
Okamura et al. Imaging of activity of multidrug resistance–associated protein 1 in the lungs
JP6990934B2 (ja) 異所性脂肪蓄積治療用ａ３アデノシン受容体リガンド
AU2020201980A1 (en) Combination of FXR agonists
Rajani et al. Post-infarct morphine treatment mitigates left ventricular remodeling and dysfunction in a rat model of ischemia-reperfusion
Cerqueira Advances in pharmacologic agents in imaging: new A2A receptor agonists
Caillier et al. Metabolic syndrome potentiates the cardiac action potential-prolonging action of drugs: a possible ‘anti-proarrhythmic’role for amlodipine
Higashi et al. Severity of hypertension affects improved resistance artery endothelial function by angiotensin-converting enzyme inhibition
Nakamura et al. Oral administration of a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity for pulmonary arterial hypertension
Pelleg et al. The first second-generation adenosine drug enters the US market
Zhou et al. Altered purinergic signaling in uridine adenosine tetraphosphate-induced coronary vasodilation in swine with diabetes mellitus type 2
Glover The vasodilatory and cardioprotective properties of A2A adenosine receptor agonists
Thackeray Examination of altered sympathetic nervous function in obesity and diabetes mellitus using [¹¹C] meta-hydroxyephedrine.
Kilbourn et al. Effects of a lobelane analog on [11C] DTBZ binding to the VMAT2
Clapp Interactions of Prostacyclin and Endothelin.
Herman 3.4 Identification of Dexrazoxane as a Cardioprotector
WO2009028420A1 (ja) 冠動脈の描出能改善剤